Premium
Echocardiographic evaluation of the effects of gallopamil on left ventricular function
Author(s) -
Fisman Enrique Z,
Pines Amos,
BenAri Efraim,
Shiner Robert J,
Drory Yaacov,
Friedman Basil A,
Kellermann Jan J
Publication year - 1988
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1988.119
Subject(s) - gallopamil , medicine , contractility , ejection fraction , ventricular function , placebo , cardiology , morning , anesthesia , calcium , heart failure , nifedipine , alternative medicine , pathology
Two‐dimensional echocardiography was used to determine global and regional left ventricular function in 32 patients treated with gallopamil (methoxyverapamil) for angina pectoris. Ejection fraction (EF), pressure/volume ratio (PVR), and segmental wall motion were assessed. Evaluations were made before therapy (T 1 and repeated 3 weeks later; this assessment included examination 2 and 8 hours after the morning dose (T 2 and T 3 , respectively). Patients were randomized to either a placebo group or three study groups (25, 37.5, and 50 mg t.i.d.). In the 37.5 and 50 mg groups there was an increase in EF (T 1 = 53.8% and 54.5%, T 2 = 57.9% and 60.1%, and T 3 = 57.6% and 60%) and PVR values (T 1 = 5.2 and 7.2 mm Hg/ml/m 2 , T 2 = 5.8 and 7.7 mm Hg/ml/m 2 , and T 3 = 5.9 and 7.6 mm Hg/ml/m 2 , respectively). Wall motion remained the same or improved in 92.3% of the patients. In conclusion, gallopamil had no cardiodepressant effects in most patients. On the contrary, EF, PVR, and segmental contractility tended to improve with the higher doses. Clinical Pharmacology and Therapeutics (1988) 44, 100–106; doi: 10.1038/clpt.1988.119